Palivizumab epitope–displaying virus-like particles protect rodents from RSV challenge

Respiratory syncytial virus (RSV) is the most common cause of serious viral bronchiolitis in infants, young children, and the elderly. Currently, there is not an FDA-approved vaccine available for RSV, though the mAb palivizumab is licensed to reduce the incidence of RSV disease in premature or at-r...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Invest
Autori principali: Schickli, Jeanne H., Whitacre, David C., Tang, Roderick S., Kaur, Jasmine, Lawlor, Heather, Peters, Cory J., Jones, Joyce E., Peterson, Darrell L., McCarthy, Michael P., Van Nest, Gary, Milich, David R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2015
Soggetti:
Technical Advance
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4409022/
https://ncbi.nlm.nih.gov/pubmed/25751145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI78450
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi